MET kinase inhibitor reverses resistance to entrectinib induced by hepatocyte growth factor in tumors with NTRK1 or ROS1 rearrangements

BACKGROUND: Entrectinib is an effective drug for treating solid tumors with NTRK gene rearrangement and non‐small cell lung cancer (NSCLC) with ROS1 gene rearrangement. However, its efficacy is limited by tolerance and acquired resistance, the mechanisms of which are not fully understood. The growth...

Descripción completa

Detalles Bibliográficos
Autores principales: Takumi, Yohei, Arai, Sachiko, Suzuki, Chiaki, Fukuda, Koji, Nishiyama, Akihiro, Takeuchi, Shinji, Sato, Hiroki, Matsumoto, Kunio, Sugio, Kenji, Yano, Seiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028024/
https://www.ncbi.nlm.nih.gov/pubmed/36416133
http://dx.doi.org/10.1002/cam4.5342

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028024/
https://www.ncbi.nlm.nih.gov/pubmed/36416133
http://dx.doi.org/10.1002/cam4.5342

Ejemplares similares